In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography

Brain

Volumn 138, Issue 3, 2015, Pages 549-562

  Kollmer, Jennifer ^a   Hund, Ernst ^a   Hornung, Benjamin ^a   Hegenbart, Ute ^a   Schonland, Stefan O ^a   Kimmich, Christoph ^a   Kristen, Arnt V ^a   Purrucker, Jan ^a   Rocken, Christoph ^b   Heiland, Sabine ^a   Bendszus, Martin ^a   Pham, Mirko ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Amyloid polyneuropathy; hereditary amyloidosis; MR imaging; MR neurography; Transthyretin familial amyloid polyneuropathy

Indexed keywords

PREALBUMIN; ALBUMIN RECEPTOR; AMYLOID; TRANSTHYRETIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GENE; GENE MUTATION; HISTOGRAM; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LONGITUDINAL STUDY; MAGNETIC RESONANCE NEUROGRAPHY; MALE; MIDDLE AGED; NERVE INJURY; NERVE LESION; NEUROGRAPHY; NEUROPATHY DEFICIT AND NEUROPATHY SYMPTOM SCORE; NEUROPATHY IMPAIRMENT SCORE LOWER LIMB; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RELAXATION TIME; SCORING SYSTEM; SPINAL NERVE; BIOPSY; CASE CONTROL STUDY; GENETICS; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MUTATION; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERIPHERAL NERVE INJURIES; PHYSIOLOGY; RADIOGRAPHY;

ADULT; AGED; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; BIOPSY; CASE-CONTROL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEURAL CONDUCTION; PERIPHERAL NERVE INJURIES; PROSPECTIVE STUDIES; RECEPTORS, ALBUMIN;

EID: 84927979896     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu344     Document Type: Article

References (59)

1. Abbas Z, Gras V, Mollenhoff K, Keil F, Oros-Peusquens AM, Shah NJ. Analysis of proton-density bias corrections based on T measurement for robust quantification of water content in the brain at 3 Tesla. Magn Reson Med 2014; 72: 1735-45.
2. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123 (Pt 7): 1495-504.
3. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013; 20: 8-31.
4. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-27.
5. Bendszus M, Stoll G. Technology insight: visualizing peripheral nerve injury using MRI. Nat Clin Pract Neurol 2005; 1: 45-53.
6. Benson MD. Familial amyloidotic polyneuropathy. Trends Neurosci 1989; 12: 88-92.
7. Benson M. Amyloidosis. In: Scriver CR, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 4159-91.
8. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996; 47: 944-51.
9. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658-67.
10. Bril V. NIS-LL: the primary measurement scale for clinical trial end-points in diabetic peripheral neuropathy. Eur Neurol 1999; 41 (Suppl 1): 8-13.
11. Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000; 51: 543-69.
12. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785-92.
13. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369: 819-29.
14. Coutinho P, Martins Da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy: review in 483 cases. In: Glenner GG, Pinho P, Costa E, Falcao De Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88.
15. Davies GR, Ramani A, Dalton CM, Tozer DJ, Wheeler-Kingshott CA, Barker GJ, et al. Preliminary magnetic resonance study of the macromolecular proton fraction in white matter: a potential marker of myelin? Mult Scler 2003; 9: 246-9.
16. De Navasquez S, Treble HA. A case of primary generalized amyloid disease with involvement of the nerves. Brain 1938; 61: 116-28.
17. Dyck PJ, Lambert EH. Dissociated sensation in amyloidosis: compound action potentials; quantitative histologic and teased fibers; and electron microscopic studies of sural nerve biopsies. Trans Am Neurol Assoc 1968; 93: 112-5.
18. Dyck PJ, Karnes JL, O'Brien P, Okazaki H, Lais A, Engelstad J. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol 1986a; 19: 440-9.
19. Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986b; 19: 425-39.
20. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21-32.
21. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229-39.
22. Dyck PJ, Norell JE. Microvasculitis and ischemia in diabetic lumbosa-cral radiculoplexus neuropathy. Neurology 1999; 53: 2113-21.
23. Enderlein G. Scheffé, H.: The analysis of variance. Wiley, New York 1959. Biom J 1961; 3: 143-4.
24. Filler AG, Howe FA, Hayes CE, Kliot M, Winn HR, Bell BA, et al. Magnetic resonance neurography. Lancet 1993; 341: 659-61.
25. Gioeva Z, Urban P, Meliss RR, Haag J, Axmann HD, Siebert F, et al. ATTR amyloid in the carpal tunnel ligament is frequently of wild-type transthyretin origin. Amyloid 2013; 20: 1-6.
26. Hanyu N, Ikeda S, Nakadai A, Yanagisawa N, Powell HC. Peripheral nerve pathological findings in familial amyloid polyneuropathy: a correlative study of proximal sciatic nerve and sural nerve lesions. Ann Neurol 1989; 25: 340-50.
27. Heiland S, Sartor K, Martin E, Bardenheuer HJ, Plaschke K. In vivo monitoring of age-related changes in rat brain using quantitative diffusion magnetic resonance imaging and magnetic resonance relaxometry. Neurosci Lett 2002; 334: 157-60.
28. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-6.
29. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40: 242-6.
30. Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 2001; 56: 431-5.
31. Hund E. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis. Appl Clin Genet 2012; 5: 37-41.
32. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. Fsl. Neuroimage 2012; 62: 782-90.
33. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The trans-thyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012; 421: 185-203.
34. Kebbel A, Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 2006; 30: 673-83.
35. Kelly JJ Jr, Kyle RA, O'Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol 1979; 6: 1-7.
36. Kollmer J, Baumer P, Milford D, Dombert T, Staub F, Bendszus M, et al. T2-signal of ulnar nerve branches at the wrist in guyon's canal syndrome. PLoS One 2012; 7: e47295.
37. Merlini G, Plante-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013; 6: 1011-20.
38. Pham M, Oikonomou D, Baumer P, Bierhaus A, Heiland S, Humpert PM, Nawroth PP, et al. Proximal neuropathic lesions in distal symmetric diabetic polyneuropathy: findings of high-resolution magnetic resonance neurography. Diabetes Care 2011; 34: 721-3.
39. Pham M, Baumer P, Meinck HM, Schiefer J, Weiler M, Bendszus M, et al. Anterior interosseous nerve syndrome: fascicular motor lesions of median nerve trunk. Neurology 2014; 82: 598-606.
40. Plante-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 1998; 51: 708-14.
41. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10: 1086-97.
42. Rajani B, Rajani V, Prayson RA. Peripheral nerve amyloidosis in sural nerve biopsies: a clinicopathologic analysis of 13 cases. Arch Pathol Lab Med 2000; 124: 114-118.
43. Reilly M. Hereditary amyloid neuropathy. In: Dyck PJ, editor. Peripheral neuropathy. Vol. 2. Elsevier Saunders: Philadelphia; 2005. p. 1921-35.
44. Said G, Ropert A, Faux N. Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: a clinicopathologic study. Neurology 1984; 34: 1025-32.
45. Said G, Plante-Bordeneuve V. Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci 2009; 284: 149-54.
46. Said G, Plante-Bordeneuve V. TTR-familial amyloid polyneuropathy-neurological aspects. Amyloid 2012; 19 (Suppl 1): 25-7.
47. Schonland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012; 119: 488-93.
48. Shahani BT, Halperin JJ, Boulu P, Cohen J. Sympathetic skin re-sponse-a method of assessing unmyelinated axon dysfunction in peripheral neuropathies. J Neurol Neurosurg Psychiatry 1984; 47: 536-42.
49. Shivji ZM, Ashby P. Sympathetic skin responses in hereditary sensory and autonomic neuropathy and familial amyloid neuropathy are different. Muscle Nerve 1999; 22: 1283-6.
50. Simmons Z, Blaivas M, Aguilera AJ, Feldman EL, Bromberg MB, Towfighi J. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci 1993; 120: 60-3.
51. Sousa MM, Saraiva MJ. Neurodegeneration in familial amyloid poly-neuropathy: from pathology to molecular signaling. Prog Neurobiol 2003; 71: 385-400.
52. Stoll G, Bendszus M. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging. Neuroscience 2009; 158: 1151-60.
53. Stoll G, Bendszus M, Perez J, Pham M. Magnetic resonance imaging of the peripheral nervous system. J Neurol 2009; 256: 1043-51.
54. Sugimura K, Dyck PJ. Multifocal fiber loss in proximal sciatic nerve in symmetric distal diabetic neuropathy. J Neurol Sci 1982; 53: 501-9.
55. Thomas PK, King RH. Peripheral nerve changes in amyloid neuropathy. Brain 1974; 97: 395-406.
56. Tofts PS, du Boulay EP. Towards quantitative measurements of relaxation times and other parameters in the brain. Neuroradiology 1990; 32: 407-15.
57. Tojo K, Sekijima Y, Kelly JW, Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006; 56: 441-9.
58. Van Allen MW, Frohlich JA, Davis JR. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology 1969; 19: 10-25.
59. Yumlu S, Barany R, Eriksson M, Rocken C. Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. Hum Pathol 2009; 40: 1655-60.